{"product_id":"sln-vrio-analysis","title":"Silence Therapeutics plc (SLN): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eDiscover the true engine behind Silence Therapeutics plc (SLN)'s competitive edge! This VRIO analysis cuts straight to the core, revealing precisely which of its resources are truly Valuable, Rare, Inimitable, and Organized for success. Uncover the secrets to their sustainable advantage - or the critical gaps they must address - by diving into the full breakdown below.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSilence Therapeutics plc (SLN) - VRIO Analysis: 1. Proprietary mRNAi GOLD™ Platform\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at the core engine behind Silence Therapeutics plc’s value proposition, and honestly, it’s the platform that makes the pipeline tick. This mRNAi GOLD™ technology is their proprietary way of creating short interfering RNAs (siRNAs) that go straight to the liver to silence disease-causing genes. Think of it as a highly specialized delivery truck for genetic medicine, and the liver is the perfect, high-value target organ for many systemic diseases.\u003c\/p\u003e\n\u003cp\u003eThe platform’s \u003cstrong\u003eValue\u003c\/strong\u003e is clear: it has already delivered two significant, wholly-owned candidates. Zerlasiran, targeting lipoprotein(a) for cardiovascular risk, showed a median maximum reduction of 90% or greater in Phase 2 data. Divesiran, for polycythemia vera, just completed enrollment for its Phase 2 SANRECO study as of October 2025, with topline data due in Q3 2026. That’s real clinical progress built on this tech.\u003c\/p\u003e\n\u003cp\u003eFor \u003cstrong\u003eRarity\u003c\/strong\u003e, while other firms use siRNA, Silence Therapeutics’ validated, systemic liver-targeting capability isn't something every smaller player has locked down. It takes serious, sustained investment to get this right. Look at the financials: they spent $20.5 million on R\u0026amp;D in the third quarter of 2025 alone. This level of focused spend backs up the claim that this isn't easily duplicated.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e is high because this isn't a single drug; it’s a complex, multi-year technology stack. Replicating the specific chemistry, delivery mechanisms, and the resulting clinical data takes years and significant capital. The fact that their pipeline, including both Zerlasiran and Divesiran, is entirely built on this foundation shows deep organizational commitment to the platform, which speaks to high \u003cstrong\u003eOrganization\u003c\/strong\u003e. They executed on the Divesiran enrollment target by year-end 2025, showing they can manage the pipeline built on this core asset.\u003c\/p\u003e\n\u003cp\u003eThe resulting \u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e leans toward sustained, but it’s always contingent on the next data readout. If Zerlasiran moves successfully into Phase 3 and Divesiran hits its Q3 2026 milestone, the platform’s sustained advantage is cemented by its proven ability to generate clinical candidates that address large markets (Lp(a) targets up to 20% of the global population). You defintely need to watch those Q3 2026 results closely.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math on the platform’s current backing:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue (as of Sep 30, 2025)\u003c\/td\u003e\n\u003ctd\u003eImplication\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$102.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRunway extends into \u003cstrong\u003e2028\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 R\u0026amp;D Spend\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$20.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSustained investment in platform evolution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZerlasiran Efficacy\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e~90%\u003c\/strong\u003e Lp(a) reduction\u003c\/td\u003e\n\u003ctd\u003ePlatform validation in cardiovascular space\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDivesiran Next Readout\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eQ3 2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eKey inflection point for hematology asset\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eWhat this estimate hides is the dependency on successful Phase 3 trials for Zerlasiran and the ultimate commercialization path. Still, the platform itself is the moat.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAssess partnership potential for pipeline assets.\u003c\/li\u003e\n\u003cli\u003eModel valuation impact of Q3 2026 Divesiran data.\u003c\/li\u003e\n\u003cli\u003eReview burn rate against $102.2 million cash position.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSilence Therapeutics plc (SLN) - VRIO Analysis: 2. Zerlasiran Phase 2 Data Package (Lp(a) Silencing)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Demonstrates a median maximum Lp(a) reduction of approximately \u003cstrong\u003e90%\u003c\/strong\u003e or greater in high-risk patients.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Near-total knockdown of Lp(a) is rare; Lp(a) levels $\\ge$ \u003cstrong\u003e125 nmol\/L\u003c\/strong\u003e affect approximately \u003cstrong\u003e20%\u003c\/strong\u003e of the world's population.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; other companies are pursuing Lp(a), but this specific data set is unique to Silence Therapeutics.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate; the company has completed core Phase 3 readiness activities, including manufacturing and supply scale up.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the advantage relies on maintaining this efficacy lead until a partner is secured and Phase 3 data is generated.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePhase 2 ALPACAR-360 Trial Statistics:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTrial enrolled \u003cstrong\u003e178\u003c\/strong\u003e subjects.\u003c\/li\u003e\n\u003cli\u003eMedian baseline Lp(a) was approximately \u003cstrong\u003e215 nmol\/L\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eReductions in Lp(a) persisted at the final visit, \u003cstrong\u003e60 weeks\u003c\/strong\u003e following initial drug administration.\u003c\/li\u003e\n\u003cli\u003eThe company paused initiation of the Phase 3 cardiovascular outcomes study pending a partner.\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents, and short-term investments were \u003cstrong\u003e$114.2 million\u003c\/strong\u003e as of June 30, 2025, expected to fund operational plans into \u003cstrong\u003e2028\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eDosing Regimen\u003c\/td\u003e\n\u003ctd\u003eMedian Maximum Lp(a) Reduction (Week 36)\u003c\/td\u003e\n\u003ctd\u003eMean Time-Averaged Placebo-Adjusted Reduction (36 Weeks)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e300 mg Q16 weeks\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e−96.4%\u003c\/strong\u003e (95% CI, \u003cstrong\u003e−97.7%\u003c\/strong\u003e to \u003cstrong\u003e−92.3%\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e−82.8%\u003c\/strong\u003e (95% CI, \u003cstrong\u003e−88.2%\u003c\/strong\u003e to \u003cstrong\u003e−77.4%\u003c\/strong\u003e)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e300 mg Q24 weeks\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e−90.0%\u003c\/strong\u003e (95% CI, \u003cstrong\u003e−93.7%\u003c\/strong\u003e to \u003cstrong\u003e−81.3%\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e−81.3%\u003c\/strong\u003e (95% CI, \u003cstrong\u003e−86.7%\u003c\/strong\u003e to \u003cstrong\u003e−76.0%\u003c\/strong\u003e)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e450 mg Q24 weeks\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e−94.5%\u003c\/strong\u003e (95% CI, \u003cstrong\u003e−97.3%\u003c\/strong\u003e to \u003cstrong\u003e−84.2%\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e−85.6%\u003c\/strong\u003e (95% CI, \u003cstrong\u003e−90.9%\u003c\/strong\u003e to \u003cstrong\u003e−80.3%\u003c\/strong\u003e)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eSilence Therapeutics plc (SLN) - VRIO Analysis: 3. Divesiran Clinical Momentum in PV\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePotential as first-in-class siRNA targeting TMPRSS6 for Polycythemia Vera (PV).\u003c\/li\u003e\n\u003cli\u003ePhase 1 data showed maintenance of mean hematocrit (HCT) levels at $\\le$ \u003cstrong\u003e45%\u003c\/strong\u003e across all dose cohorts in 21 patients.\u003c\/li\u003e\n\u003cli\u003ePhase 1 results essentially eliminated the need for therapeutic phlebotomies in patients with a combined history of 79 prior phlebotomies.\u003c\/li\u003e\n\u003cli\u003ePrimary endpoint for Phase 2 is proportion of patients maintaining HCT $\\le$ 45% without phlebotomies between weeks 18 and 36.\u003c\/li\u003e\n\u003cli\u003eElevated HCT above 45% is associated with a four-times higher rate of death from cardiovascular or thrombotic events.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eHighly effective, non-invasive siRNA approach is novel in the PV space.\u003c\/li\u003e\n\u003cli\u003eReceived FDA Fast Track and Orphan Drug designations for PV.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePhase 2 SANRECO study has completed enrollment of 48 phlebotomy-dependent PV patients.\u003c\/li\u003e\n\u003cli\u003ePhase 2 dosing intervals being evaluated are every six weeks and every 12 weeks.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eSANRECO Phase 1 Data\u003c\/th\u003e\n\u003cth\u003eSANRECO Phase 2 Design\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients Enrolled\/Targeted\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e21\u003c\/strong\u003e (Phlebotomy-dependent)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e48\u003c\/strong\u003e (Phlebotomy-dependent)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrior Phlebotomy History (Combined)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e79\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A (Dependent on phlebotomies)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHCT Control Endpoint\u003c\/td\u003e\n\u003ctd\u003eMean HCT $\\le$ \u003cstrong\u003e45%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eProportion maintaining HCT $\\le$ \u003cstrong\u003e45%\u003c\/strong\u003e without phlebotomies (Wks 18-36)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDosing Frequency\u003c\/td\u003e\n\u003ctd\u003eEvery \u003cstrong\u003e6 weeks\u003c\/strong\u003e (4 doses)\u003c\/td\u003e\n\u003ctd\u003eEvery \u003cstrong\u003e6 weeks\u003c\/strong\u003e and every \u003cstrong\u003e12 weeks\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePhase 2 enrollment completed as of October 2025.\u003c\/li\u003e\n\u003cli\u003eInitial topline results anticipated in the third quarter of 2026 (Q3 2026).\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents, and short-term investments of $102.2 million as of September 30, 2025.\u003c\/li\u003e\n\u003cli\u003eCash runway guidance into 2028.\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D expenses for Q3 2025 were $20.5 million.\u003c\/li\u003e\n\u003cli\u003eG\u0026amp;A expenses for Q3 2025 were $5.8 million.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eLead based on being first-to-market with compelling data in a rare disease focus area.\u003c\/li\u003e\n\u003cli\u003eAnticipated topline data in Q3 2026 provides a near-term catalyst.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSilence Therapeutics plc (SLN) - VRIO Analysis: 4. Expanding RNAi Intellectual Property Estate\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The patent portfolio, including historical 'Zamore Design Rules,' provides a defensive moat and potential licensing revenue from third parties. Collaboration Revenue for the year ended December 31, 2024, was \u003cstrong\u003e$43.1 million\u003c\/strong\u003e. Research and development expenses for the same period were \u003cstrong\u003e$67.9 million\u003c\/strong\u003e, which includes activities to enhance the value in underlying intellectual property.\u003c\/p\u003e\n\u003cp\u003eThe foundational 'Zamore Design Rule' patent families, exclusively licensed by Silence Therapeutics in the human healthcare field from the University of Massachusetts Medical School, include the following reaffirmed U.S. Patents:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePatent Number\u003c\/th\u003e\n\u003cth\u003eFocus Area\u003c\/th\u003e\n\u003cth\u003eStatus Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS 7,459,547\u003c\/td\u003e\n\u003ctd\u003eRNAi agent structural modifications\u003c\/td\u003e\n\u003ctd\u003eReaffirmed by USPTO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS 7,732,593\u003c\/td\u003e\n\u003ctd\u003eReducing off-target gene expression silencing\u003c\/td\u003e\n\u003ctd\u003eReaffirmed by USPTO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS 7,772,203\u003c\/td\u003e\n\u003ctd\u003eControlling Efficacy of RNA Silencing\u003c\/td\u003e\n\u003ctd\u003eReaffirmed by USPTO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS 7,750,144\u003c\/td\u003e\n\u003ctd\u003eRNAi agent structural modifications\u003c\/td\u003e\n\u003ctd\u003eReaffirmed by USPTO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; foundational IP in the RNAi space, especially around chemical modifications for efficacy, is scarce. The Zamore Design Rules describe methods fundamental to the creation of RNA-based therapeutics.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; patents legally block direct imitation of the claimed methods and compositions, including methods of enhancing silencing activity of RNAi agents through structural modifications.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the company actively upholds its patent estate globally. As of December 31, 2024, the global patent portfolio contained:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e\u003cstrong\u003e21\u003c\/strong\u003e\u003c\/strong\u003e solely owned patent families.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/strong\u003e jointly owned patent families.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe company's cash and cash equivalents, and short-term investments were \u003cstrong\u003e$147.3 million\u003c\/strong\u003e at the end of December 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, as long as key patents remain in force, offering long-term protection. The company's proprietary mRNAi.GOLD™ platform is utilized for both internal pipeline development and out-licensed programs.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSilence Therapeutics plc (SLN) - VRIO Analysis: 5. Strategic Partnership Network and Validation\n\u003c\/h2\u003e\n\n\u003cp\u003eThe strategic partnership network provides external validation of the mRNAi GOLD™ platform and contributes non-dilutive funding streams.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: Collaborations with major players like AstraZeneca validate the platform and provide non-dilutive funding and access to broader therapeutic areas.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe collaboration with AstraZeneca, initiated in March 2020, included an upfront investment of \u003cstrong\u003e$80 million\u003c\/strong\u003e, composed of \u003cstrong\u003e$60 million\u003c\/strong\u003e in cash and a \u003cstrong\u003e$20 million\u003c\/strong\u003e equity investment.\u003c\/li\u003e\n\u003cli\u003eFor each of the up to \u003cstrong\u003eten\u003c\/strong\u003e targets in the AstraZeneca deal, Silence is eligible for an option fee of \u003cstrong\u003e$10 million\u003c\/strong\u003e upon candidate nomination.\u003c\/li\u003e\n\u003cli\u003eThe Hansoh collaboration, initiated in October 2021, included an upfront payment of \u003cstrong\u003e$16 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company received a \u003cstrong\u003e$10 million\u003c\/strong\u003e milestone payment from AstraZeneca following the initiation of a Phase 1 clinical trial for the first product candidate.\u003c\/li\u003e\n\u003cli\u003eA \u003cstrong\u003e$2.0 million\u003c\/strong\u003e cash payment was received from Hansoh following the achievement of the second undisclosed milestone related to the first target (as of June 2024).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: Moderate; many biotechs have partnerships, but securing deals with top-tier firms is selective.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe number of active, high-value, multi-target platform collaborations with top-tier pharmaceutical companies is a measure of rarity.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003ePlatform Focus\u003c\/th\u003e\n\u003cth\u003eUpfront\/Initial Payment\u003c\/th\u003e\n\u003cth\u003eTotal Potential Milestones (Excl. Royalties)\u003c\/th\u003e\n\u003cth\u003eMax Targets\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAstraZeneca\u003c\/td\u003e\n\u003ctd\u003eCVRM diseases (Liver, Heart, Lung, etc.)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$80 million\u003c\/strong\u003e (Cash + Equity)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$3.9 billion\u003c\/strong\u003e (Up to \u003cstrong\u003e$390 million\u003c\/strong\u003e per target)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e10\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHansoh Pharma\u003c\/td\u003e\n\u003ctd\u003eThree undisclosed targets\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$1.3 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: Low; the specific agreements and the history of collaboration are unique to Silence Therapeutics.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe specific terms and the cumulative success in achieving milestones are difficult to replicate.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe AstraZeneca deal structure allows for up to \u003cstrong\u003e$140 million\u003c\/strong\u003e in development milestones and up to \u003cstrong\u003e$250 million\u003c\/strong\u003e in commercialization milestones per target.\u003c\/li\u003e\n\u003cli\u003eThe Hansoh deal provides tiered royalties on net product sales ranging from \u003cstrong\u003elow double-digit to mid-teens\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe AstraZeneca collaboration includes tiered royalties on net sales ranging from \u003cstrong\u003ehigh single digit to low double digit\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe Hansoh collaboration milestone achievement in June 2024 represented the \u003cstrong\u003efourth\u003c\/strong\u003e research milestone payment achieved under that agreement.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: High; the company uses a pragmatic, flexible approach to deal-making, which attracts partners.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe company's internal structure supports the execution and management of these complex agreements.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSilence is responsible for the discovery stage up to candidate nomination, after which AstraZeneca assumes responsibility and costs for further development.\u003c\/li\u003e\n\u003cli\u003eSilence retains the option to co-develop \u003cstrong\u003etwo\u003c\/strong\u003e programs discovered through the AstraZeneca collaboration starting from Phase II.\u003c\/li\u003e\n\u003cli\u003eThe AstraZeneca collaboration is focused on developing siRNA therapeutics for Cardiovascular, Renal, Metabolic, and Respiratory diseases.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Sustained; the established relationships create a network effect for future deals.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe successful progression of programs validates the platform for future potential partners.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe initiation of a Phase 1 trial for the first AstraZeneca program marked the \u003cstrong\u003ethird\u003c\/strong\u003e program from the mRNAi GOLD™ platform to enter the clinic (as of February 2024).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSilence Therapeutics plc (SLN) - VRIO Analysis: 6. Deep, Liver-Targeting Expertise\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOver 20-plus years of experience, with siRNA work beginning in 1998 in Berlin research labs. The mRNAi GOLD™ platform utilizes a GalNAc ligand for highly specific delivery to liver tissues\/cells, targeting a subset of the approximately 14,000 genes expressed in the liver.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh; institutional knowledge base developed through a focus shift to GalNAc siRNA between 2005-2007. The platform underpins 14+ partnered programs in addition to wholly owned assets.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh; this specialized knowledge is demonstrated through the tangible, quantifiable success of the platform's outputs:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePlatform Component\/Metric\u003c\/th\u003e\n\u003cth\u003eQuantifiable Data Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eExperience Start Year\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1998\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiver Gene Expression Capacity\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e14,000\u003c\/strong\u003e genes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZerlasiran Efficacy (Max Reduction)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e99%\u003c\/strong\u003e Lp(a) reduction at \u003cstrong\u003e90 days\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDivesiran Efficacy (Hematocrit Control)\u003c\/td\u003e\n\u003ctd\u003eDurable control below \u003cstrong\u003e45%\u003c\/strong\u003e in PV patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartnered Programs Utilizing Platform\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e14+\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAstraZeneca Milestone Value\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$10 million\u003c\/strong\u003e triggered by Phase 1 entry\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh; this expertise is the foundation for clinical progress:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eZerlasiran (SLN360) in cardiovascular disease, achieving up to 99% reduction in Lp(a) at 90 days in a Phase 1 study.\u003c\/li\u003e\n\u003cli\u003eDivesiran (SLN124) in Polycythemia Vera (PV), demonstrating durable hematocrit control below 45% in the SANRECO Phase 1 study.\u003c\/li\u003e\n\u003cli\u003eThe platform enabled the initiation of a Phase 1 trial for the first AstraZeneca collaboration candidate, triggering a $10 million milestone payment.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSustained; the institutional experience, evidenced by the 1998 patent filing and the $10 million milestone achieved from the AstraZeneca collaboration, represents deep, embedded capabilities difficult to replicate.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSilence Therapeutics plc (SLN) - VRIO Analysis: 7. Wholly-Owned Pipeline Depth Beyond Leads\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The presence of multiple wholly-owned assets provides optionality outside of major partnerships. Divesiran (SLN124) for Polycythemia Vera (PV) has completed enrollment in the SANRECO Phase 2 study, which enrolled \u003cstrong\u003e48\u003c\/strong\u003e phlebotomy-dependent PV patients, with initial topline results anticipated in the \u003cstrong\u003ethird quarter of 2026\u003c\/strong\u003e. The planned Phase 1 study for SLN548 for complement-mediated diseases was paused as of Q2 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; having multiple clinical-stage assets across hematology, cardiovascular disease, and complement-mediated diseases is a sign of a healthy, diversified platform.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; the ability to generate multiple clinical-ready candidates, such as Zerlasiran (SLN360) in Phase 2 and Divesiran (SLN124) in Phase 2, is a sign of strong internal R\u0026amp;D leveraging the mRNAi GOLD™ platform.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate; the company is clearly allocating resources to advance these internally, evidenced by Research \u0026amp; Development expenses of \u003cstrong\u003e$20.5 million\u003c\/strong\u003e for the quarter ended September 30, 2025, and a cash position of \u003cstrong\u003e$102.2 million\u003c\/strong\u003e providing a runway into \u003cstrong\u003e2028\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; this advantage erodes if the pipeline candidates fail to progress, as seen with the decision to pause the initiation of the SLN548 Phase 1 study.\u003c\/p\u003e\n\u003cp\u003eThe wholly-owned pipeline depth includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eZerlasiran (SLN360): Phase \u003cstrong\u003e2\u003c\/strong\u003e clinical trial for cardiovascular disease associated with elevated lipoprotein(a).\u003c\/li\u003e\n\u003cli\u003eDivesiran (SLN124): Phase \u003cstrong\u003e1\/2\u003c\/strong\u003e clinical trial for Polycythemia Vera (PV).\u003c\/li\u003e\n\u003cli\u003eSLN548: Phase \u003cstrong\u003e1\u003c\/strong\u003e study paused.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eWholly-Owned Indication\u003c\/th\u003e\n\u003cth\u003eLatest Clinical Stage\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDivesiran (SLN124)\u003c\/td\u003e\n\u003ctd\u003ePolycythemia Vera (PV)\u003c\/td\u003e\n\u003ctd\u003ePhase \u003cstrong\u003e2\u003c\/strong\u003e (Enrollment complete)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZerlasiran (SLN360)\u003c\/td\u003e\n\u003ctd\u003eCardiovascular Disease (elevated Lp(a))\u003c\/td\u003e\n\u003ctd\u003ePhase \u003cstrong\u003e2\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSLN548\u003c\/td\u003e\n\u003ctd\u003eComplement-Mediated Diseases\u003c\/td\u003e\n\u003ctd\u003ePhase \u003cstrong\u003e1\u003c\/strong\u003e (Initiation paused)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eSilence Therapeutics plc (SLN) - VRIO Analysis: 8. Extended Financial Runway into 2027\/2028\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The decision to pause Zerlasiran Phase 3 initiation extends the projected cash runway into \u003cstrong\u003e2028\u003c\/strong\u003e, providing operational flexibility and reducing immediate financing risk.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many clinical-stage biotechs face constant funding pressure; this buffer is a strength.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; this is a result of past financing activities, such as ending 2024 with \u003cstrong\u003e$147.3 million\u003c\/strong\u003e in cash, cash equivalents, and short-term investments, and current capital management decisions.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the CFO explicitly linked the runway extension into \u003cstrong\u003e2027\u003c\/strong\u003e (initially) and subsequently reiterated into \u003cstrong\u003e2028\u003c\/strong\u003e to a strategic decision on Zerlasiran.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; this is a finite resource that will be depleted by R\u0026amp;D spending, which was \u003cstrong\u003e$17.6 million\u003c\/strong\u003e in the quarter ended \u003cstrong\u003eJune 30, 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eKey financial metrics supporting the runway assessment:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\/Date\u003c\/th\u003e\n\u003cth\u003eSource\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Cash Runway End\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003e2028\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Position (End of 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$147.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Position (End of Q2 2025)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$114.2 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses (Q2 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZerlasiran Phase II Lp(a) Reduction (48 weeks)\u003c\/td\u003e\n\u003ctd\u003eMedian maximum reduction of around \u003cstrong\u003e90%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe strategic context for the runway extension includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe decision to only initiate the Zerlasiran Phase 3 cardiovascular outcomes study once a partner is secured.\u003c\/li\u003e\n\u003cli\u003ePrioritization of investment in programs targeting rare conditions, such as Divesiran in Polycythemia Vera (PV), with full enrollment in the SANRECO Phase 2 study anticipated by year-end 2025.\u003c\/li\u003e\n\u003cli\u003eThe prior Hansoh Pharma collaboration, which provided an upfront payment of \u003cstrong\u003e$16 million\u003c\/strong\u003e, was terminated, meaning milestone payments from that arrangement will not be realized.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSilence Therapeutics plc (SLN) - VRIO Analysis: 9. Strategic Focus on High Unmet Need Areas\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Concentrating resources on cardiovascular, hematology, and rare diseases aligns development with areas where regulatory pathways can be clearer and pricing power higher. The global cardiovascular disease drugs' market size is expected to reach $186.1 billion by 2032. Zerlasiran targets up to 1.4 billion worldwide living with high Lp(a).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many companies chase broad indications; this focused approach is a deliberate strategic choice.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; this is a strategic decision, not a physical asset, but it guides resource allocation.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; CEO Craig Tooman stated in February 2025 that in 2025, they are prioritizing investment in programs targeting rare conditions where they believe they can deliver on clear unmet needs.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, provided the company maintains discipline in sticking to this focused strategy.\u003c\/p\u003e\n\u003cp\u003ePipeline focus areas supporting this strategy include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eZerlasiran for Cardiovascular Disease (high Lp(a)).\u003c\/li\u003e\n\u003cli\u003eDivesiran for Polycythemia Vera (PV) in Hematology; Phase 2 SANRECO study enrollment on-track to complete by year-end 2025.\u003c\/li\u003e\n\u003cli\u003eSLN548 for Complement-Mediated Diseases; Phase 1 study planned for the second half of 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinancial metrics supporting resource allocation:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ1 2025 (as of 3\/31\/25)\u003c\/td\u003e\n\u003ctd\u003eQ2 2025 (as of 6\/30\/25)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Short-term Investments\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$136.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$114.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$20.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$28.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$27.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Runway Guidance\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003e2028\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003e2028\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516252250261,"sku":"sln-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/sln-vrio-analysis.png?v=1740215092","url":"https:\/\/dcf-model.com\/fr\/products\/sln-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}